Cosentyx Shown to Reduce Fatigue for Up to 3 Years in Active AS Patients

Cosentyx Shown to Reduce Fatigue for Up to 3 Years in Active AS Patients

281760

Cosentyx Shown to Reduce Fatigue for Up to 3 Years in Active AS Patients

Treatment with Cosentyx (secukinumab) reduced fatigue for up to three years in people with active ankylosing spondylitis (AS), particularly those who had never received TNF inhibitors, according to two Phase 3 clinical trials. Age and disease activity before the treatment were found to predict short-term fatigue reductions, while fatigue severity and functional limitations predicted long-term improvements.  The study, “Secukinumab Provides Sustained Reduction in Fatigue in Patients with Ankylosing Spondylitis: Long‐term Results of Two Phase III…

You must be logged in to read/download the full post.